8.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$8.96
Aprire:
$8.95
Volume 24 ore:
11.70M
Relative Volume:
0.96
Capitalizzazione di mercato:
$11.10B
Reddito:
$15.05B
Utile/perdita netta:
$-883.30M
Rapporto P/E:
-11.95
EPS:
-0.74
Flusso di cassa netto:
$1.89B
1 W Prestazione:
-6.36%
1M Prestazione:
-7.24%
6M Prestazione:
-23.46%
1 anno Prestazione:
-25.27%
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VTRS
Viatris Inc
|
8.84 | 11.10B | 15.05B | -883.30M | 1.89B | -0.74 |
![]()
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-07-19 | Ripresa | Jefferies | Buy |
2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
2022-10-21 | Ripresa | Jefferies | Hold |
2022-06-14 | Iniziato | UBS | Sell |
2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
2021-06-15 | Iniziato | Citigroup | Neutral |
2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
2021-03-08 | Downgrade | Goldman | Buy → Neutral |
2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2021-01-05 | Iniziato | Argus | Hold |
2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are - Bluefield Daily Telegraph
Viatris Inc. Announcement: If You Have Suffered Losses in - GlobeNewswire
The Global Market for Paclitaxel Injections Presents an - GlobeNewswire
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris – VTRS - TradingView
The Human Factor: Device Stress Tests Run Gamut to Mimic Real-World Use - Viatris
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible - GlobeNewswire
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman - TradingView
Is Viatris Inc. (NASDAQ:VTRS) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
VTRS Investor News: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action InvestigationVTRS - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
Viatris Inc. Being Investigated on Behalf of Viatris Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
VTRS Stock Quote - richtv.io
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS) - ACCESS Newswire
Did Viatris Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateVTRS - ACCESS Newswire
VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action InvestigationVTRS - PR Newswire
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2025 -February 27, 2025 at 06:30 am EST - Marketscreener.com
Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now? - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider.com
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc.VTRS - PR Newswire
Viatris Inc. Under Investor Scrutiny: Levi & Korsinsky Launches Securities Investigation - Apna Kal
Viatris Stock Plummets Over 15% Amid Earnings Miss and FDA Warning – Investors Encouraged to Take Action - Apna Kal
Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation – VTRS - Bluefield Daily Telegraph
Viatris Inc (VTRS) Volatility Hits 3.27% – Here Is What You Should Do - Stocks Register
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Shareholders to Reach Out - Markets Insider
Investors who Lost Money on Viatris Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationVTRS - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PR Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds - Investing.com
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds By Investing.com - Investing.com UK
Viatris Inc. (VTRS) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Viatris at Barclays Conference: Strategic Moves Amid Challenges - Investing.com
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations - ACCESS Newswire
ATTENTION Viatris Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Viatris Inc. (VTRS) And Encourages Investors to Connect - Markets Insider
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):